OraSure Technologies, Inc. (OSUR)

OraSure Technologies' stock price experienced a decline of 35.04% from January 27, 2025, to January 23, 2026. Key events impacting the stock include the Q3 2025 Earnings Report, the acquisition of Sherlock Biosciences, director nominations from Altai Capital, FDA Submissions, and Q4 2024 Financial Results. The company reported an EPS of -$0.13, beating analyst estimates of -$0.16, but quarterly revenue was $27.09 million, falling below analyst estimates of $28.96 million. Total net revenue for Q3 2025 decreased 32% year-over-year to $27.1 million, driven by declines in both major segments. The company also reported a GAAP operating loss of $16.1 million in Q3 2025, a significant widening from Q3 2024.

Demand seasonality for OraSure Technologies' products and services is influenced by public health funding, COVID-19 related sales, and consumer genomics customer orders. A significant portion of the Diagnostics revenue is tied to government and non-governmental organization (NGO) public health funding, which has shown volatility. The company experienced a sharp decline in COVID-19 test sales, and the Sample Management business has faced a sharp decline in orders from a large consumer genomics customer. To mitigate these demand fluctuations, OraSure is actively diversifying its customer base and investing in new product launches.

OraSure Technologies, Inc. is a diagnostic and medical device company specializing in point-of-care and self-testing products. The company's core business revolves around oral fluid and other non-invasive sample collection technologies used for detecting infectious diseases, drugs of abuse, and health and wellness biomarkers. Major products include the OraQuick® rapid HIV test, OraQuick® HCV Rapid Antibody Test, Intercept® and OraSure® brands, collection devices, COVID-19 antigen and antibody tests, Sample Management Solutions (SMS), Sherlock Molecular Diagnostics platform, and SickleScan rapid point-of-need test.

OraSure Technologies' headquarters and largest manufacturing facility are located in Bethlehem, Pennsylvania. The company has wholly-owned subsidiaries, including DNA Genotek in Ottawa, Canada, and Sherlock Biosciences, with locations in Newton, Massachusetts, and the United Kingdom. OraSure's products are distributed globally to healthcare providers, public health agencies, clinical laboratories, and consumers in over 100 countries across North America, Europe, and Asia.

OraSure Technologies' brand reputation in the past year appears to be positively influenced by its commitment to decentralizing diagnostics and improving healthcare accessibility. The company has continued its work with the Centers for Disease Control and Prevention's (CDC) "Together Take Me Home HIV self-test program," achieved prequalification status from the World Health Organization (WHO) for its OraQuick® HCV Self-Test, and acquired Sherlock Biosciences in December 2024.

OraSure Technologies, Inc. is a publicly traded company with its ownership distributed among many shareholders. Institutional investors are the dominant owners, holding a significant majority of its shares, commonly reported above 80% and as high as 93.50% as of August 2025. Insider ownership is in the low single digits. Major institutional owners include BlackRock, Inc., Private Management Group Inc, Neuberger Berman Group LLC, Vanguard Group Inc, Altai Capital Management, L.P., Dimensional Fund Advisors Lp, Systematic Financial Management Lp, Renaissance Technologies Llc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, and Acadian Asset Management Llc.